Search results
Results From The WOW.Com Content Network
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
ATC code N06 Psychoanaleptics is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Intuniv - an extended release, non-stimulant alpha-2 adrenergic agonist used to treat attention deficit hyperactivity disorder. Available in instant-release under the brand-name Tenex . Invega ( paliperidone ) – atypical antipsychotic used to treat schizophrenia and schizoaffective disorder
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
This article lists veterinary pharmaceutical drugs alphabetically by name. Many veterinary drugs have more than one name and, therefore, the same drug may be listed more than once. Abbreviations are used in the list as follows: INN = International Nonproprietary Name; BAN = British Approved Name; USAN = United States Adopted Name
The medication was discontinued in 2002 for commercial reasons. [6] [13] [14] However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021. [6] [15] [16] Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance. [1]
Attention deficit hyperactivity disorder predominantly inattentive (ADHD-PI or ADHD-I), [3] is one of the three presentations of attention deficit hyperactivity disorder (ADHD). [4] In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R).